FRK

Tyrosine-protein kinase FRK

93,056 patent compounds predicted against FRK, 75,656 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sb-203580 (SCHEMBL95208)	0.75	4/20
SCHEMBL69095	0.67	4/20
SCHEMBL67376	0.64	4/20
SCHEMBL66923	0.60	4/20
SCHEMBL67192	0.60	4/20
SCHEMBL68165	0.59	4/20
SCHEMBL90887	0.49	4/20
SCHEMBL90935	0.49	4/20
SCHEMBL68193	0.67	3/20
SCHEMBL68360	0.67	3/20
SCHEMBL67345	0.64	3/20
SCHEMBL67898	0.64	3/20
SCHEMBL66986	0.59	3/20
SCHEMBL67603	0.59	3/20
SCHEMBL84724	0.59	3/20
SCHEMBL67577	0.58	3/20
SCHEMBL70028	0.58	3/20
SCHEMBL57834	0.58	3/20
SCHEMBL59666	0.58	3/20
SCHEMBL59667	0.58	3/20

Germline variants in FRK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full FRK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to FRK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.	PHASE3	COMPLETED
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer	PHASE2	WITHDRAWN
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients	PHASE2	ENROLLING_BY_INVITATION
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC	PHASE2	UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer	PHASE2	COMPLETED
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations	PHASE1/PHASE2	RECRUITING
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	PHASE1/PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers	PHASE1	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen	nan	UNKNOWN
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FRK binder may also engage these)

Protein	Name	Similarity
TXK	Tyrosine-protein kinase TXK	1.000	landscape →
Q922K9	—	0.999	Q922K9 →
Q62662	—	0.998	Q62662 →
Q0VBZ0	—	0.998	Q0VBZ0 →
P63185	—	0.997	P63185 →
P25020	—	0.996	P25020 →
P50545	—	0.996	P50545 →
P35991	—	0.995	P35991 →
P41241	—	0.995	P41241 →
P31693	—	0.994	P31693 →
P17713	—	0.994	P17713 →
P00528	—	0.994	P00528 →
ITK	Tyrosine-protein kinase ITK/TSK	0.993	landscape →
Q6P6U0	—	0.993	Q6P6U0 →
P00526	—	0.993	P00526 →
P42683	—	0.993	P42683 →
P00525	—	0.993	P00525 →
P32577	—	0.992	P32577 →
CSK	Tyrosine-protein kinase CSK	0.992	landscape →
Q64434	—	0.992	Q64434 →
P42686	—	0.992	P42686 →
P39688	—	0.992	P39688 →
O45539	—	0.992	O45539 →
P06240	—	0.991	P06240 →
YES1	Tyrosine-protein kinase Yes	0.991	landscape →
Q6EWH2	—	0.990	Q6EWH2 →
BTK	Tyrosine-protein kinase BTK	0.990	landscape →
Q01621	—	0.990	Q01621 →
P00524	—	0.989	P00524 →
HCK	Tyrosine-protein kinase HCK	0.989	landscape →